Skip to Main Content

Paper Details

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Cell Death Dis
10
2022
B, B-cell receptor, BAX, BCR, BTK, Bcl-2, Bcl-2 network, Bcl-xL, Bruton tyrosine kinase, CG-806, CRISPR, Cas9, MCL, MCL PDX models, MCL cell lines, MYC, Mcl-1, NF, NFKBIA, SYK, anti-apoptotic Bcl-2 family proteins, diffuse large B-cell lymphoma, hematologic malignancies, ibrutinib, ibrutinib-resistant MCL cell lines, luxeptinib, lymphoid malignancies, mantle cell lymphoma, patient, patient-derived MCL cells, patients, primary MCL cells, resistant model, tyrosine
Adult, Agammaglobulinaemia Tyrosine Kinase, Cell Line, Tumor, Humans, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-bcl-2, Pyrazoles, Pyrimidines, Receptors, Antigen, B-Cell, Syk Kinase, Tumor Microenvironment
Author NameAffiliation
Elana ThiemeCity of Hope National Medical Center
Tingting LiuCity of Hope National Medical Center
Nur BrussKnight Cancer Institute, Oregon Health and Science University
Carly RolederCity of Hope National Medical Center
Vi LamCity of Hope National Medical Center
Xiaoguang WangCity of Hope National Medical Center
Tamilla NechiporukKnight Cancer Institute, Oregon Health and Science University
Tamilla NechiporukOregon Health & Science University
Geoffrey ShouseCity of Hope National Medical Center
Olga V DanilovaCity of Hope National Medical Center
Daniel BottomlyKnight Cancer Institute, Oregon Health and Science University
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University
Shannon K McWeeneyOregon Clinical and Translational Research Institute
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
Jeffrey W TynerOregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Stephen E KurtzKnight Cancer Institute, Oregon Health and Science University
Stephen E KurtzOregon Health & Science University
Alexey V DanilovCity of Hope National Medical Center
Alexey V DanilovKnight Cancer Institute, Oregon Health and Science University
  • 1 - 22

Datasets

Release 1.2